Protagonist Therapeutics, Inc.

NasdaqGM:PTGX 株式レポート

時価総額：US$6.8b

Protagonist Therapeutics マネジメント

マネジメント 基準チェック /24

Protagonist Therapeuticsの CEO はDinesh Patelで、 Dec2008年に任命され、 の在任期間は 17.5年です。 の年間総報酬は$ 12.87Mで、 5.6%給与と94.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.45%を直接所有しており、その価値は$ 30.43M 。経営陣と取締役会の平均在任期間はそれぞれ5.4年と11.4年です。

主要情報

Dinesh Patel

最高経営責任者

US$12.9m

報酬総額

CEO給与比率5.56%
CEO在任期間17.5yrs
CEOの所有権0.4%
経営陣の平均在職期間5.4yrs
取締役会の平均在任期間11.4yrs

経営陣の近況

Recent updates

分析記事 • May 15

This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year

Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) shareholders will have a reason to smile today, with the analysts making...
分析記事 • May 08

Protagonist Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) last week reported its latest first-quarter results, which makes it a...
Seeking Alpha • Jan 30

Protagonist Therapeutics: Assessing The 2026 Upside For Icotrokinra And Rusfertide

Summary Protagonist Therapeutics remains a high-conviction buy, driven by late-stage assets icotrokinra and rusfertide approaching regulatory milestones in 2026. PTGX’s robust cash position of $678.8 million provides a runway through 2028, supporting aggressive R&D and upcoming commercialization efforts. Both icotrokinra and rusfertide have demonstrated strong efficacy and safety in pivotal trials, with regulatory submissions underway and significant market opportunities ahead. Valuation is premium at 21x EV/sales, reflecting high investor expectations for late-stage pipeline success; downside risk remains if approvals falter. Read the full article on Seeking Alpha
分析記事 • Oct 11

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues

Despite an already strong run, Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) shares have been powering on, with a gain...
分析記事 • Jun 13

Subdued Growth No Barrier To Protagonist Therapeutics, Inc. (NASDAQ:PTGX) With Shares Advancing 27%

Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) shareholders would be excited to see that the share price has had a...
Seeking Alpha • Mar 11

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It

Summary Protagonist Therapeutics, Inc. achieved primary endpoint in a phase 3 VERIFY study using rusfertide in polycythemia vera and the phase 2b ANTHEM-UC study using icotrokinra in ulcerative colitis. Icotrokinra, a first-in-class IL-23 receptor agonist, shows promise in treating ulcerative colitis and plaque psoriasis, potentially shifting treatment paradigms in both of these indications. Financially stable with $559.2 million in cash and recent milestone payments, Protagonist can fund operations through 2028, reducing financial risk. Future PTGX prospects include expanding icotrokinra's use to Crohn's Disease and initiating phase 1 study for PN-881, targeting immune-mediated disorders like hidradenitis suppurativa. Read the full article on Seeking Alpha
Seeking Alpha • Jan 13

Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck

Summary Positive results achieved from both ICONIC studies using JNJ-2113 for the treatment of patients with moderate-to-severe plaque psoriasis; Superiority study is data expected in Q2 of 2025. Topline results from the phase 3 VERIFY study, using rusfertide for the treatment of patients with polycythemia vera, expected in Q1 of 2025. The global Polycythemia vera market size is expected to grow to $2.03 billion by 2032. The company had $583.3 million in cash as of September 30th of 2024; Enough cash to fund its operations until the end of 2027. Read the full article on Seeking Alpha
Seeking Alpha • Oct 16

The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey

Summary Today, we circle back to the clinical stage of biopharma Protagonist Therapeutics, Inc., whose stock has tripled over the past year. The company has two late-stage drug candidates that are partnered with Takeda and Johnson & Johnson, respectively. If pivotal trials turn out to be successful, both drugs could be approved in 2026. Still more upside in this rally? An updated analysis of Protagonist Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Feb 25

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Summary Protagonist Therapeutics' stock has experienced significant volatility over the past three years, with multiple setbacks and recoveries. The company's lead drug candidate, Rusfertide, indicated for polycythemia vera, faced a clinical hold from the FDA but had the hold removed in October 2021 and now looks approvable. Protagonist's joint plaque psoriasis candidate, JNJ-2113, showed positive results in a Phase 2 study, leading to a stock price increase. Both of Protagonist's lead candidates make a case for a commercial approval - although not for 2 more years at least, and there are risks, and hurdles still to be overcome. 2 Phase 3 studies must still be completed. The recently signed deal with Takeda to co-commercialise Rusfertide is a significant boost for Protagonist and has driven its market cap valuation to $1.64bn - I think that is an accurate reflection for its value for now, but may look to buy on any dips. Read the full article on Seeking Alpha
Seeking Alpha • Jun 08

Protagonist: Too Many Red Flags

Protagonist has recently faced a number of mishaps. These make the stock risky. They have a good deal of cash for now.
Seeking Alpha • Feb 01

Protagonist Is Still Being Undervalued Like There's Real Risk

Protagonist Therapeutics is currently working to tackle some serious issues with an underserved form of blood cancer. A recent cancer scare sent shockwaves through the company's valuation, and it has been almost entirely resolved. The current valuation is still a deep discount from the highs prior to the dip.

CEO報酬分析

Protagonist Therapeutics の収益と比較して、Dinesh Patel の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

-US$115m

Dec 31 2025US$13mUS$716k

-US$130m

Sep 30 2025n/an/a

US$46m

Jun 30 2025n/an/a

US$52m

Mar 31 2025n/an/a

US$56m

Dec 31 2024US$9mUS$681k

US$275m

Sep 30 2024n/an/a

US$171m

Jun 30 2024n/an/a

US$170m

Mar 31 2024n/an/a

US$162m

Dec 31 2023US$7mUS$655k

-US$79m

Sep 30 2023n/an/a

-US$140m

Jun 30 2023n/an/a

-US$138m

Mar 31 2023n/an/a

-US$140m

Dec 31 2022US$6mUS$630k

-US$127m

Sep 30 2022n/an/a

-US$130m

Jun 30 2022n/an/a

-US$133m

Mar 31 2022n/an/a

-US$122m

Dec 31 2021US$6mUS$600k

-US$126m

Sep 30 2021n/an/a

-US$108m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$70m

Dec 31 2020US$2mUS$565k

-US$66m

Sep 30 2020n/an/a

-US$65m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$83m

Dec 31 2019US$2mUS$545k

-US$77m

報酬と市場: Dineshの 総報酬 ($USD 12.87M ) は、 US市場 ($USD 8.38M ) の同規模の企業の平均を上回っています。

報酬と収益: Dineshの報酬は増加しましたが、会社は利益を上げていません。

CEO

Dinesh Patel (69 yo)

17.5yrs
在職期間
US$12,871,506
報酬

Dr. Dinesh V. Patel, Ph D., has been the Chief Executive Officer, President and Director at Protagonist Therapeutics, Inc. since December 2008 and serves as its Secretary. He serves as Additional Non-Execu...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Dinesh Patel
CEO, President17.5yrsUS$12.87m0.45%
$ 30.4m
Asif Ali
Executive VP & CFO4.2yrsUS$3.26m0.0040%
$ 271.7k
Arturo Molina
Chief Medical Officer3.6yrsUS$4.10m0.021%
$ 1.4m
Venkat Thalladi
EVP & Chief Technical Officerless than a yearデータなしデータなし
Newman Yeilding
Executive VP1.8yrsデータなしデータなし
Matthew Gosling
Executive VP and Chief Legal & Business Officer5.8yrsデータなしデータなし
Carena Spivey
Executive VP & Chief Human Resources Officer5.4yrsデータなしデータなし
Ashok Bhandari
EVP & Chief Discovery Officer5.4yrsデータなしデータなし
Carter King
Executive Vice President of Business Development5.2yrsデータなしデータなし
Abha Bommireddi
Executive VP & Chief of Staff5.4yrsデータなしデータなし
Samuel Saks
Clinical Development Advisor5.4yrsデータなしデータなし
5.4yrs
平均在職期間
62yo
平均年齢

経験豊富な経営陣: PTGXの経営陣は経験豊富で経験豊富です（平均在職期間は5.4年）。

取締役

名称ポジション在職期間報酬所有権
Dinesh Patel
CEO, President17.5yrsUS$12.87m0.45%
$ 30.4m
Harlan Weisman
Clinical Advisor11.4yrsデータなしデータなし
Lewis Williams
Independent Director9yrsUS$431.82k0.0080%
$ 543.3k
Chaitan Khosla
Chairman of Scientific Advisory Board11.4yrsUS$188.07kデータなし
Harold Selick
Independent Chairman17.3yrsUS$428.07k0.090%
$ 6.2m
William Waddill
Independent Director9.9yrsUS$431.82k0.0080%
$ 543.3k
Charles Craik
Scientific Advisorno dataデータなしデータなし
Mark Gallop
Scientific Advisorno dataデータなしデータなし
Wayne Lencer
Clinical Advisorno dataデータなしデータなし
Aida Habtezion
Clinical Advisorno dataデータなしデータなし
Ellen Scherl
Clinical Advisorno dataデータなしデータなし
Bryan Giraudo
Independent Director8.1yrsUS$431.82k0.016%
$ 1.1m
11.4yrs
平均在職期間
69yo
平均年齢

経験豊富なボード: PTGXの 取締役会 は経験豊富で 経験豊富 です ( 11.4年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/06/10 01:15
終値2026/06/10 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Protagonist Therapeutics, Inc. 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。19

アナリスト機関
Etzer DaroutBarclays
Evan SeigermanBMO Capital Markets Equity Research
Timothy ChiangCapital One Securities, Inc.